

Yatharth Hospital & Trauma Care Services Limited

CIN No.: L85110DL2008PLC174706

YH/SE/82/2025-26
February 05, 2026

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1
G Block, Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051, India

Symbol: YATHARTH
ISIN: INE0JO301016

Dept. of Listing Operations
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001, India

Scrip Code: 543950
ISIN: INE0JO301016

Subject: Investor's Presentation- Q3 FY26 Results

Dear Sir/Madam,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor's Presentation on financial results of the Company for the Q3 FY26.

The above presentation will also be made available on website of the Company at <https://www.yatharthhospitals.com/investors>

This is for your kind information and records.

Thanking You

Yours Faithfully,
For Yatharth Hospital & Trauma Care Services Limited

Ritesh Mishra
Company Secretary & Compliance Officer
M. No. A51166

Encl.: A/a

Registered Office

JA-108, DLF Tower A, Jasola District Centre, New Delhi-110025
Tel: 011-49967892

Corporate Office

Sovereign Capital Gate, FC-I2, Sec-16A, Noida-201301
Tel: 0120-6811236 | Email: cs@yatharthhospitals.com
Web: www.yatharthhospitals.com

Our Hospitals

- 📍 Sector Omega-01, Greater Noida, Uttar Pradesh-201308
- 📍 Sector-01, Greater Noida West, Uttar Pradesh-201306
- 📍 Sector-110, Noida, Uttar Pradesh-201304
- 📍 Jhansi Mauranipur Highway, Orchha, Madhya Pradesh-472246
- 📍 Sector-88, Faridabad, Haryana-121002
- 📍 4C Institutional Area, North Extension, Model Town 3, New Delhi-110009
- 📍 Plot No. 9 & 9A, Sector 20B, Faridabad, Haryana-121001



Q3 & 9M FY26 Earnings Presentation

February 5, 2026

Disclaimer



Certain matters discussed in this presentation may contain statements regarding the company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements does not guarantee future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the economy, industry, competition, the company's ability to successfully implement its strategy, technological implementation, changes and advancements, the company's market preferences and its exposure to market risks, as well as other risks. The company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this presentation. The company assumes no obligation to update any forward-looking information contained in this presentation. Any forward-looking statements and projections made by third parties included in this presentation are not adopted by the company and the company is not responsible for such third-party statements and projections. You are cautioned not to place undue reliance on these forward-looking statements, which are based on the current view of the management of the Company on future events.

Q3 & 9M FY26 Highlights



Financial Snapshot for Q3 FY26



Revenue

Rs. 3,205 mn

+46% YoY



EBITDA

Rs. 742 mn

+35% YoY



EBITDA Margin

23.2%



PAT

Rs. 431 mn

+41% YoY



Bed Capacity²

2,550+ beds



Occupancy³

67%

+11% YoY



ARPOB

Rs. 33,744

+10% YoY



ALOS

4.32

Adjusted for initial ramp up losses of New Delhi and Faridabad Sec-20, Group's **Adjusted EBITDA Margin stood robust at 29.2%**, led by operating leverage, mix improvement and positive impact of price revisions in government business

1. Adjusted EBITDA Margin excluding the impact of New Delhi and Faridabad Sec-20 hospitals

2. 2,305 beds, excluding Agra hospital (250 beds), which is integrated w.e.f. Feb 1, 2026

3. Occupancy has been computed on actual days of operations for newly opened hospitals

Growth in Action, with ramp up of Delhi and Faridabad Hospital




Sec-20, Faridabad



Commenced
Sep-25

Bed Capacity
400 Beds

Model Town, New Delhi



Commenced
July-25

Bed Capacity
300 Beds

- ❖ Acquisition of Sec-20 Faridabad hospital coupled with the earlier acquisition of Greater Faridabad hospital, positions Yatharth Hospitals as one of the **largest hospitals in the Faridabad region**

Latest Monthly Revenue Rate

Rs. 7-8 crore, within 3 months of operations

From 100% Cash & TPA and 0% Government Business

Latest ARPOB

Rs. 36k

- ❖ Catering to a **large catchment of residential and institutional client base** in the region. Model Town hospital **strengthens Yatharth Hospitals presence** in the attractive market of Delhi

Latest Monthly Revenue Rate

Rs. 5 crore+, within 4 months of operations

From 100% Cash & TPA and 0% Government Business

Latest ARPOB

Rs. 40k

Within first full quarter of operations, Faridabad Sec-20 and New Delhi generated **Rs. 279 mn revenue**, contributing **9%** to Group's revenues

Successful Integration of Agra Hospital w.e.f. February 2026



Well Established **Multi-Speciality Hospital**



Built across **~1,65,000 sq. ft.**



Bed Capacity **250 Beds**




100% stake acquired at **Rs. 260 Cr**



Integrated w.e.f. **Feb 1, 2026**

To contribute meaningfully to both Revenue and EBITDA from Day 1 of integration

- ❖ Located in **Agra**, Uttar Pradesh, on **NH-19**, serving nearby catchment areas with underpenetrated quality medical infrastructure
- ❖ Proximity to **Yamuna Expressway connecting Gr. Noida with Agra**, would serve as a feeder to the Group's hospitals for Oncology and Organ Transplants



Estimated Population In Lakhs

Strengthening Governance: Inspiring Trust for Our Stakeholders



 Appointment of MSKA & Associates as statutory auditors (a member firm of BDO International)

MSKA & Associates
Chartered Accountants

127%

Shareholder Return
since listing

 Appointment of Mr. Ramesh Krishnan as Independent Director, a seasoned healthcare leader with 30+ yrs of experience.



 Induction of Deloitte as an Internal Auditor to strengthen governance mechanisms

Deloitte.

MSCI 

Constituent of the MSCI India Small Cap Index, effective from Aug 26, 2025

 Institutionalisation – addition of Management Bandwidth, along with existing Group CEO & Group CFO



Nitin Gupta
Group COO &
President –
Finance



Ashutosh Kumar Jha
Group Chief, Strategy,
M&A and IR




Sonu Goyal
Group Finance
Controller

A/Stable
CRISIL Rating


Financial Performance: Strongest-ever Quarter




Revenue (Rs mn)



EBITDA (Rs mn) & EBITDA%




PBT (Rs mn) & PBT%




PAT (Rs mn) & PAT%



Operational Performance: Improvement across Clinical Parameters



Diversifying Revenue across Hospitals




- **New hospitals continued to drive growth momentum, with New Delhi and Faridabad Sec-20 contributing Rs. 279 mn – 9% of the Group's revenues—within their first full quarter of operations**
- **Existing hospitals¹ also sustained strong performance, delivering a robust 33% YoY revenue growth**

Note: Mature Hospitals comprises of Noida, Greater Noida and Noida Extension, while all other Hospitals are classified as New Hospitals

1. Existing Hospitals are Noida, Greater Noida, Noida Extension, Jhansi-Orchha and Greater Faridabad

*Including Agra hospital, which has been integrated w.e.f. Feb 1, 2026

Expanding High Value Specialities across Hospitals



Noida Extension recording its highest-ever ARPOB at Rs. 44k (+16% YoY). New hospitals demonstrated a strong ARPOB—New Delhi at Rs. 40k, Faridabad Sec-20 at Rs. 36k, and Greater Faridabad at Rs. 34k—reflecting focus on driving high-value case & payer mix

Profit & Loss Summary



| Particulars (Rs mn) | Q3FY26 | Q3FY25 | Change YoY | Q2FY26 | Change QoQ | 9MFY26 | 9MFY25 | Change YoY |
|--------------------------------|--------------|--------------|------------------|--------------|------------------|--------------|--------------|------------------|
| Revenue from Operations | 3,205 | 2,192 | 46% | 2,794 | 15% | 8,577 | 6,487 | 32% |
| Medical Consumables & Pharmacy | 625 | 421 | 48% | 564 | 11% | 1,724 | 1,320 | 31% |
| Employee Expenses | 635 | 426 | 49% | 538 | 18% | 1,655 | 1,187 | 39% |
| Other Expenses | 1,202 | 796 | 51% | 1,047 | 15% | 3,165 | 2,348 | 35% |
| EBITDA | 742 | 549 | 35% | 645 | 15% | 2,033 | 1,632 | 25% |
| EBITDA Margin % | 23.2% | 25.1% | (189) Bps | 23.1% | 8 Bps | 23.7% | 25.2% | (146) Bps |
| Depreciation and amortisation | 240 | 169 | 42% | 189 | 27% | 578 | 443 | 30% |
| Financial Cost | 10 | 21 | (51%) | 3 | 296% | 15 | 65 | (78%) |
| Other Income | 78 | 42 | 86% | 95 | (18%) | 266 | 108 | 146% |
| Profit Before Tax (PBT) | 571 | 402 | 42% | 548 | 4% | 1,706 | 1,232 | 38% |
| Tax | 140 | 97 | 45% | 136 | 3% | 442 | 314 | 41% |
| Profit After Tax (PAT) | 431 | 305 | 41% | 413 | 4.4% | 1,264 | 918 | 38% |
| PAT Margin % | 13.4% | 13.9% | (47) Bps | 14.8% | (132) Bps | 14.7% | 14.2% | 58 Bps |




At a Glance

Leading Group of Super Speciality Hospitals in North India



One-stop destination for patient needs providing comprehensive quaternary healthcare services



2,550+
Bed Capacity

Rs. 32,757
ARPOB

66%
Occupancy

Revenue
+40%
4Y CAGR

EBITDA
+35%
4Y CAGR

PAT
+61%
4Y CAGR



Noida Extension facility accredited by JCI




All our facilities are NABH accredited



NABL accredited for our leading hospitals


Our Growth Journey



Backed by Marquee Investors, Focused on Shareholder Value Growth



| Key Investors | |
|-----------------------------------|--------------------------------|
| Kotak Mahindra Mutual Fund | Jupiter India |
| Bandhan Mutual Fund | Marval Capital |
| Motilal Oswal Mutual Fund | Blackrock |
| Groww Mutual Fund | State Street Corp |
| Canara HSBC Life Insurance | Millingtonia Capital |
| Universal Sompo General Insurance | Abu Dhabi Investment Authority |
| Carnelian Capital | Param Capital (Mukul Agarwal) |
| Guardian Capital | Kedia Securities (Vijay Kedia) |



One of the Fastest Expanding Hospital Networks



Mature



Greater Noida

2010 Incorporated

400 Beds; **112** ICU Beds

(expandable to 600 beds)



Noida

2013 Incorporated

250 Beds; **81** ICU Beds



Noida Extension

2019 Incorporated

450 Beds; **125** ICU Beds

(expandable to 700 beds)

Jhansi – Orchha

2022 Acquisition

305 Beds; **76** ICU Beds



Greater Faridabad

2024 Acquisition

200 Beds; **72** ICU Beds



New Delhi

2025 Commencement

300 Beds; **74** ICU Beds



Faridabad

2025 Commencement

400 Beds; **75** ICU Beds



Agra

2025 Acquisition

250 Beds; **56** ICU Beds



New

Clinical Excellence Backed by Cutting-Edge Infrastructure



DaVinci Robotic Systems



Minimally invasive precision cancer, urological, gastrointestinal, cardiothoracic, gynaecological surgeries and kidney transplants

Imaging Department



State-of-the-art equipments - MRI, CT scan, mammography, bone densitometer, ECHO, 4D ultrasound, digital X-ray, TMT, EEG, EMG, Dexa-scan, Denta-scan, RVG, and OPG

LINAC Machine



Advanced radiotherapy procedure for safe and precise cancer treatment

PET CT Machine



Latest generation with Respiratory gated 4D

Joint Replacement Robots



Precise Joint Replacement - Total knee, total hip and partial knee replacement

Cath Lab



Wide detector & tilt table for cardiovascular & neuro-Interventional procedures, advanced 3D imaging & CT-like clarity

| Complex Procedures | Presence in Hospitals | No. of Procedures performed till date |
|-----------------------|---|---------------------------------------|
| Organ Transplants | Noida Ext. & Gr. Noida | 230+ |
| Robotic Surgeries | All Hospitals (excl. Noida & Jhansi-Orchha) | 950+ |
| Radiation Oncology | Noida Ext | 2,900+ |
| Cardiac Procedures | All Hospitals | 9,600+ |
| Neuro Surgeries | All Hospitals | 6,800+ |
| Orthopaedic Surgeries | All Hospitals | 20,300+ |

DNB program to attract medical talent

19
Specialties

74
Resident Doctors

Noida
Noida Ext
Gr. Noida

Strategically Positioned to Capture Medical Value Travel Opportunities




Market Development & Brand Building

- ❖ Cardiac partnership in Ethiopia with Children's Heart Fund and Black Lion Hospital; IVF CME and patient screening conducted in Mauritius
- ❖ Engagements with government officials, private hospitals and doctors across Uzbekistan, Tajikistan, Nigeria, Afghanistan and Turkmenistan
- ❖ Establishment of representative office at Tashkent & Baghdad as an MVT hub for CIS market
- ❖ Expansion into Cameroon through institutional and private tie-ups
- ❖ International outreach with OPD operations in Mauritius, Nigeria, and Turkmenistan
- ❖ Conducted Super Speciality and Healthcare partner engagement events to strengthen ties across Africa and Iraq

Upcoming

- ❖ Yatharth Information Centres to launch in Tajikistan, Mauritius, Tanzania and Kenya

Our Proximity to Jewar Airport to Spur Medical Value Travel



Continuous engagement with govt. agencies & leading foreign hospitals
Established information centres, strategic tie-ups & MVT hubs across priority markets

Core Strategies Driving Growth with Clinical Excellence



Capacity Addition

Track record of successful greenfield and brownfield expansion, with an announced capacity of ~3,000 beds



Optimising Existing Infrastructure

Enhancing occupancy across our hospitals



Strengthening Clinical Infrastructure

Investing in advanced technologies and clinical talent to drive high-end specialities



Medical Value Travel

Building global patient inflow aided by commencement of Jewar Airport

Annexures




Proven Record of Consistent Financial Performance




Revenue (Rs mn)

FY21-25
CAGR @ 40%




EBITDA (Rs mn) & EBITDA%

29.3% 27.6% 25.7% 26.8% 25.0% 25.2% 23.7%




PBT (Rs mn) & PBT%

12.3% 15.7% 16.9% 23.4% 19.5%



PAT (Rs mn) & PAT%

8.6% 11.0% 12.6% 17.1% 14.8% 14.2% 14.7%




Note: Group's profitability margin drag is on account of losses from ramp up of newer hospitals and addition of Super Speciality Centres of Excellence

Consistent Performance across Operational Parameters




Bed Capacity & Occupancy (%)




ARPOB (Rs.) & ALOS (days)



IPD/OPD Revenue (Rs mn)



IPD/OPD Volume ('000s)



Thank You



Yatharth Hospital & Trauma Care Services Ltd

Investor Relations Contact

Mr. Ashutosh Kumar Jha, Group Chief – Strategy, M&A and IR

investor.relations@yatharthhospitals.com

CIN: L85110DL2008PLC174706

www.yatharthhospitals.com